ClinicalTrials.Veeva

Menu

Early CPAP in Respiratory Distress Syndrome

P

Pontificia Universidad Catolica de Chile

Status and phase

Unknown
Phase 4

Conditions

Respiratory Distress Syndrome

Treatments

Device: Early Bubble CPAP

Study type

Interventional

Funder types

Other

Identifiers

NCT00368680
NEO032006

Details and patient eligibility

About

The purpose of this study is to establish if a strategy of EBCPAP application in a subgroup of VLBWI, 800 to 1500g birthweight, decreases the need for mechanical ventilation in this group, without affecting mortality.

Full description

The application of CPAP has been described as an alternative respiratory support for premature newborns with respiratory distress.Many studies support that the early use of CPAP results in a better respiratory evolution and less need for mechanical ventilation.

Hypothesis:

  • The hypothesis is that EBCPAP will decrease the need for this more invasive therapy.

The primary endpoint in this multicenter controlled study is to establish if an strategy of EBCPAP application in a subgroup of VLBWI, 800 to 1500g birthweight, decreases the need for mechanical ventilation in this group, without affecting mortality. .

As secondary outcome, the investigators will analyse: days of oxygen therapy, days of mechanical ventilation, need for surfactant , pulmonary airleak, intraventricular hemorrhage, persistent ductus arteriosus, retinopathy of prematurity and bronchopulmonary dysplasia (BPD) at 28 days and 36 weeks corrected gestational age.

Comparison(s):

Early Bubble CPAP (EBCPAP)with Standard Therapy which is oxygen.

Enrollment

256 estimated patients

Sex

All

Ages

5 to 30 minutes old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All infants born at the units belonging to the South American Neocosur Network with a birthweight between 800 to 1500g and breathing spontaneously at birth or after hand bagging with Neopuff or transient intubation are eligible.
  • An informed consent form should be obtained preferable prenatal.

Exclusion criteria

  • Acute life threatening congenital malformations or genetics diseases.
  • Apgar score equal or less than 3 at 5 minutes
  • Disapproval of informed consent.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

14

Loading...

Central trial contact

Soledad Urzua, MD; José Luis Tapia, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems